• Explore /
  • Poster
  • / Performance of pre- and post-pembrolizumab vesical imaging–reporting and data system (VI-RADS) to predict the pathological response and efficacy outcomes in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from the PURE-01 trial.

Performance of pre- and post-pembrolizumab vesical imaging–reporting and data system (VI-RADS) to predict the pathological response and efficacy outcomes in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from the PURE-01 trial.

Abstract Poster

Authors

Chiara Mercinelli

Chiara Mercinelli

IRCCS Ospedale San Raffaele, Milan, Italy

Chiara Mercinelli , Giorgio Brembilla , Giuseppe Basile , Ewan Gibb , Daniele Raggi , Giuseppina Calareso , Tiago Costa de Padua , Laura Marandino , Damiano Alfio Patanè , Emanuele Crupi , Andrea Del Prete , Patrizia Giannatempo , Marco Moschini , Jeffrey S. Ross , Alberto Briganti , Francesco Montorsi , Antonella Messina , Francesco De Cobelli , Andrea Necchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics

Sub Track

Immunotherapies

Clinical Trial Registration Number

NCT02736266

Citation

JCO Global Oncology 9, 2023 (suppl 1; abstr 65)

DOI

10.1200/GO.2023.9.Supplement_1.65

Abstract #

65

Poster Bd #

A4

Abstract Disclosures

Similar Posters

First Author: Andrea Necchi

First Author: Chiara Mercinelli

First Author: Filippo Pederzoli

First Author: Matt D. Galsky